Kexing Pharmaceutical announced that its wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the State Drug Administration approved approval to carry out clinical trials of “GB10 injection”. The product name is GB10 injection, and the acceptance number is CXSL2500841. The approval conclusion was that this product agreed to carry out clinical trials to treat neovascular age-related macular degeneration.

Zhitongcaijing · 2d ago
Kexing Pharmaceutical announced that its wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the State Drug Administration approved approval to carry out clinical trials of “GB10 injection”. The product name is GB10 injection, and the acceptance number is CXSL2500841. The approval conclusion was that this product agreed to carry out clinical trials to treat neovascular age-related macular degeneration.